NRX Pharmaceuticals, Inc. · NASDAQ:NRXP
NRX Pharmaceuticals — Investor Presentation (October 2025)
25 slides from NRX Pharmaceuticals's investor presentation, October 2025
Slide 1: Hope Science Life
Hope Science Life NASDAQ: NRXP NRx Pharmaceuticals October 2025 © NRx - All rights reserved |
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation (this “Presentation”) is given to accredited family offices and licensed securities professionals and is provided for informational purposes only. No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fu
Slide 3: NRx – A microcap company expecting 2025 Revenue
NRx (Nasdaq:NRXP) – A microcap company expecting 2025 Revenue 2025 Filing 2026 Filing 2025 Revenue NRX-100 NRX-101 HOPE (IV Ketamine) (Oral DCS/Lurasidone) Therapeutics Interventional Psychiatry • NDA filing H2 2025 • Breakthrough Therapy • First 9 clinics Q4 2025 Bipolar Depression • FDA Fast Track
Slide 4: NRx – New Developments with Revenue Implications
NRx (Nasdaq:NRXP) – New Developments with Revenue Implications Filed 2025 IND in progress IND in progress KETAFREE NRX-100 NRX-102 (IV Ketamine) (IV Ketamine for PTSD) (Extended Release DCS) • ANDA under review • IND in progress • New finding that low-dose Depression and PTSD DCS doubles the effect
Slide 5: Suicide is a National Crisis
Suicide is a National Crisis Suicide kills >50,000 Americans every year Disproportionately affecting people with Bipolar Disorder Suicide takes our best and brightest https://www.cdc.gov/suicide/facts/index.html#:~:text=In%202021%2C%20an%20estimated%2012.3,and %201.7%20million%20attempted%20suicide.
Slide 6: For the first time, we are starting to understand Suicidality
For the first time, we are starting to understand Suicidality In our lifetimes, we have seen breakthroughs in cancer, heart disease and many other lethal conditions We have also seen a rise in suicidal depression and PTSD In the last 15 years, science is unlocking the key to Suicide • Suicidal Depre
Slide 7: FMRI in Suicidal Ideation vs. Normal
Functional Magnetic Resonance Imaging (FMRI) FMRI in Suicidal Ideation vs. Normal © NRx 2025 - All rights reserved | 7
Slide 8: Suicide is the only major cause of death not to bend the curve
Suicide is the only major cause of death not to bend the curve US Common Causes of Death Suicide Reported Unreported Unlike other common causes of death, suicide • Is allocated minimal research funding Breast Cancer 1 • Has no approved drugs Prostate Cancer 2 • Carries enormous social stigma • Can r
Slide 9: 125 Drugs for Depression and They All Cause Suicide
125 Drugs for Depression and They All Cause Suicide For 70 years, we have been looking at the wrong neurochemical pathway (serotonin) • No approved drug is shown to decrease suicidal ideation, although esketamine reduces depression in patients with suicidal ideation • Every antidepressant carries a
Slide 10: All Antidepressants Carry Black-Box Warnings for Suicidality and Akathisia
All Antidepressants Carry Black-Box Warnings for Suicidality and Akathisia no antidepressant has ever improved either side effect © NRx 2025 - All rights reserved | 11
Slide 11: Akathisia occurs in up to 15% of patients on antidepressants
Akathisia occurs in up to 15% of patients on antidepressants Akathisia is the side effect of antidepressants most closely linked to suicide • Stewart Dolin was a successful and well-liked partner at Reed Smith in Chicago. He developed an episode of depression and was treated with Paxil. That night,
Slide 12: Four Ways to Treat Suicidal Depression
Four Ways to Treat Suicidal Depression it’s time to change the paradigm and do what works Patient Total Care Umbrella Neuroplastic TMS and Other Hyperbaric Digital Drugs Neuromodulation Oxygen Therapy Therapeutics © Hope 2025 - All rights reserved | 13
Slide 13: No FDA-Approved Medication for Suicidal Ideation
No FDA-Approved Medication for Suicidal Ideation Only FDA-approved therapy is Nasal S Ketamine approved for TRD, Electro-Convulsive Therapy but not shown to decrease suicide (ECT) IV Ketamine is used off-label Ketamine Binds to the NMDA Receptor to treat Depression and Suicidality Developing NRX-100
Slide 14: Ketamine is the first prototype Neuroplastic Drug
Ketamine is the first prototype Neuroplastic Drug Ketamine’s effect on neuronal dendritic spines Chronic Stress High levels of NMDA activity are shown to cause atrophy of the “dendritic Ketamine Infusion Dendrite Baseline spines” that connect brain cells 2 Photons Imaging of neurons Loss of dendriti
Slide 15: Established Ketamine Efficacy Data
Established Ketamine Efficacy Data French Gov’t Funded: NIH Funded: PCORI Funded: Ketamine vs. Placebo Ketamine vs. Midazolam Ketamine vs. ECT • 156 Patients, 7 Hospitals • 96 pt. Randomization to Ketamine • 400 pts. superiority • Admitted with acute suicidality vs. midazolam favoring Ketamine P=.00
Slide 16: > 20,000 patients of Confirmatory Real World Data
> 20,000 patients of Confirmatory Real World Data Figure: Estimated amplitude, asymptote (plateau), shift (time until the response kicks in) and slope (speed at which the response develops once it is initiated) of intravenous ketamine (KIT) vs. nasal S-ketamine in real world experience (source: Osmi
Slide 17: New Evidence on Ketamine in PTSD
New Evidence on Ketamine in PTSD Some drugs treat symptoms of depression in PTSD. No approved drug treats the symptoms of PTSD itself Osmind, Inc. Real World Data in 8,000+ patients confirms earlier clinical trial data (N=30) demonstrating effect of IV ketamine in reducing PTSD symptoms independent
Slide 18: Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) Creates a potent neuroplastic effect in the brain TMS repairs Brain Pathways Not all TMS is Created Alike by causing Neuroplasticity Most TMS works for depression because it’s a broad target in the brain When you can aim TMS with the benefit of MRI and neurona
Slide 19: TMS with Cycloserine gives over 80% response
TMS with Cycloserine gives over 80% response • Adding a neuroplastic drug to TMS is like fertilizing the field before you plant the seed • This initial trial is now confirmed at Harvard McClean, University of Toronto and multiple other sites • Significant reduction in mean MADRS at 4 weeks with DCS
Slide 20: Reduction in Suicidality associated with DCS + TMS
Reduction in Suicidality associated with DCS + TMS • TMS + DCS is superior to placebo in association with Theta-burst Transcranial Magnetic Stimulation in reducing suicidality on the IAT scale (P<.05) • MADRS item 10 (suicidality) also showed statistically-significant reduction (P<.001) Sohn, et. al
Slide 21: Hyperbaric Oxygen Therapy and PTSD CAPS 5 Score
Hyperbaric Oxygen Therapy (HBOT) increases brain oxygenation, stimulates Neuroplasticity and may reactivate brain stem cells 40% reduction in CAPS 5 (P<.001) PTSD CAPS 5 SCORE Sham Treatment HBOT The Israel Defense Forces (IDF) has implemented HBOT Therapy for PTSD and there is pending legislation i
Slide 22: Digital Therapeutics: Gamifying our way to a cure
DIGITAL THERAPEUTICS: Gamifying our way to a cure Digital Therapeutics were • Transcendental meditation works by synchronizing breathing and developed in the military and heart rate, causing autonomic shown to reduce stress and coherence depression • It’s hard to teach and practice meditation • It’s
Slide 23: HOPE Therapeutics
HOPE Therapeutics The First National Network to Integrate Care for Depression and PTSD Now Part of the VA Community Cares Program The first network providing neuroplastic Pharmaceutical Therapy, TMS, Hyperbaric Therapy, and Digital Therapeutics, for suicidal depression, PTSD, anxiety, OCD and more.
Slide 24: HOPE Therapeutics: Cost Effectiveness of Care
HOPE Therapeutics: Cost Effectiveness of Care • Drastic improvement over four decades in the outcomes and survivability of care for common cancers, heart disease, and other lethal conditions with no improvement in survival of suicidal depression • For the first time, we are changing the survival out
Slide 25: Thank You
Thank You For further information Please contact: Jonathan Javitt, MD, MPH Chairman and CEO jjavitt@nrxpharma.com © NRx 2025 - All rights reserved | 26
NRx Pharmaceuticals — Investor Presentation (October 2025) on 6ix